INVL Private Equity Fund II, along with IFC and ACP, is set to invest in POLMED, a leading Polish private healthcare provider, to enhance its service offerings and expand into oncology through the acquisition of the KN Group.

Information on the Target

POLMED, founded in 1999, has established itself as one of the leading private healthcare service providers in Poland. With projected revenues exceeding €100 million in 2024, POLMED is known for its diverse range of services, including outpatient care, diagnostic imaging, inpatient services, and home rehabilitation. The company operates 38 facilities employing approximately 2,000 staff and collaborates with over 4,000 medical partners, serving more than 4 million patients annually and providing services to over 3,500 companies.

The upcoming acquisition of the KN Group further enhances POLMED's capabilities in the oncology sector. The KN Group comprises the Radom Oncology Centre, the Gamma Knife Centre, and the Radom Family Centre, positioned as a premier private oncology center in Poland since its establishment in 2011. This group operates three facilities in Radom and Warsaw, employing over 700 individuals and offering around 150 beds, including 14 chemotherapy chairs. Esteemed professionals, including internationally recognized neurosurgeon Prof. Mirosław Ząbek and Dorota Ząbek, will continue their leadership roles post-acquisition.

Industry Overview in Poland

Poland's healthcare sector has been evolving rapidly, primarily driven by increasing demand for quality healthcare services. The government is focused on improving healthcare infrastructure, which is crucial for patients'